Archive for Gastric / Ulcer

Testimonies BPC 157 from Biotrends clients

I personally would say that a key note to taking the BPC is about its anti-inflammatory capabilities through out the body.

Yes, it lets the body heal fast, it takes care of IBS’s

(Irritable Bowel Syndrome)

and more, but, concerning specifically anti-ageing, it’s its ability to reduce, even eliminate, swelling through out the body.

You and I both know, from our research, that swelling is a major cause of ageing.

This product is also included in their anti-ageing flagship “Rejuvenate Super Set” available here, on which you can get -10% by subscribing at the convenient monthly autoship here.

Here are a few testimonies I received from people using the PRO-HEALER BPC157 manufactured by Biotrends HK. As usual I removed the family names:

1.    Jack T.:  73 years old, Tulsa Oklahoma
I have been suffering from sore joints, tendons and slow to healing for many years now.  A friend of mine recommended I try Pro-Healer BPC-157 and I just felt I needed to write to you and let you know how much I appreciate this product.

The swelling and pain in my joints and the soreness of my tendons has diminished to the point that I often forget I had the problem.  As an added, unexpected, benefit, my stomach no longer hurts in the morning. Maybe I had an ulcer I was not aware of?  I did read that it helps, even can cure ulcers in a few days.  Thank you again.

2.   Roberta B.:  48,  Alberta Canada

This Pro-Healer has been a life saver for me.  I have been diagnosed with Crohn’s Disease for many years now.  Quite often the pain is unbelievable.  I have had to have 3 resections of my intestines so far and I was truly afraid of my future.

Now with the Pro-Healer, I never have pain, all the bloating and swelling is gone.  My doctor is amazed at the change I have had.

The only time I have had a problem since was when I stopped taking it last summer while I was travelling but I started again when I returned home and all is fine again.  I wish you could do an auto-ship for me.

3.        Stephan C.:  52,  Belgium

I am a diabetic and suffer from ulcers on my feet.  I have already lost 1 toe due to this problem.

I am very happy with the Pro-Healer as it has healed my skin ulcers in a very short amount of time.

I mixed it up, just as it shows on the box, and I apply it to all my wounds daily.  At first I thought it would not work, I suppose my expectations were very high and I was wanting instant results.

After a couple of days, however, it was very clear that they were healing and healing quickly.

I have tried so many different things but have never had these kind of results.  I believe that because of Pro-Healer I can manage to keep from loosing any more toes.  I am very happy, thank you so much.

➡ You can see this product here

➡ And register at Biotrends, it’s free here

BPC 157 Interactions in Mucosal Protection in Stress

This trial studies several mechanisms of action for BPC157.

Digestive Diseases and Sciences Journal
March 1997, Volume 42, Issue 3, pp 661-671

Pentadecapeptide BPC 157 Interactions with Adrenergic and Dopaminergic Systems in Mucosal Protection in Stress


Since superior protection against different gastrointestinal and liver lesions and anti inflammatory and analgesic activities were noted for pentadecapeptide BPC (an essential fragment of an organoprotective gastric juice protein named BPC), the beneficial mechanism of BPC 157 and its likely interactions with other systems were studied.

Hence its beneficial effects would be abolished by adrenal gland medullectomy, the influence of different agents affectingα, β, and dopamine receptors on BPC 157 gastroprotection in 48 h restraint stress was further investigated. Animals were pretreated (1 hr before stress) with saline (controls) or BPC 157 (dissolved in saline) (10 μg or 10 ng/kg body wt intra peritoneally or intra gastrically) applied either alone to establish basal conditions or, when manipulating the adrenergic or dopaminergic system, a simultaneous administration was carried out with various agents with specific effects on adrenergic or dopaminergic receptors[given in milligrams per kilogram intraperitoneally except for atenolol, which was given subcutaneously] phentolamine (10.0), prazosin (0.5),yohimbine (5.0), clonidine (0.1) (α-adrenergicdomain), propranolol (1.0), atenolol (20.0)(β-adrenergic domain), domperidone (5.0), and haloperidol(5.0) (peripheral/central dopamine system).

Alternatively, agents stimulating adrenergic ordopaminergic systemsadrenaline (5.0) or bromocriptine(10.0)-were applied. A strong protection, noted following in tragastric or intraperitoneal administration of BPC157, was fully abolished by co administration of phentolamine, clonidine, and haloperidol, andconsistently not affected by prazosin, yohimbine, ordomperidone.

Atenolol abolished only intraperitoneal BPC 157 protection, whereas propranolol affected specifically intragastric BPC 157 protection.Interestingly, the severe course of lesion developmentobtained in basal conditions, unlike BPC 157gastroprotection, was not influenced by the applicationof these agents. In other experiments, when adrenaline and bromocriptine were given simultaneously, a strong reduction of lesion development was noted.

However, when applied separately, only adrenaline, not bromocriptine, has aprotective effect. Thus, a complex protectiveinteraction with both α-adrenergic (e.g.,catecholamine release) and dopaminergic (central)systems could be suggested for both intragastric and intraperitoneal BPC 157 administration.

The involvement of β-receptor stimulation in BPC 157 gastroprotection appears to be related to the route of BPC 157 administration.The demonstration that a combined stimulation of adrenergic and dopaminergic systems by simultaneous prophylactic application of adrenaline(α- and β-receptor stimulant) and bromocriptine (dopamine receptor agonist) may significantly reduce restraint stress lesions development provides insight for further research on the beneficial mechanism of BPC 157.




Source for this article:

BPC 157 in trials for inflammatory bowel disease

This trial shows the important effectiveness of BPC157 against various lesions in gastrointestinal tract!

Inflammopharmacology Journal

Volume 14, Issue 5-6, December 2006

Gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419, safe in clinical trials for inflammatory bowel disease (PL 10, PLD 116, PLD 14736, Pliva, Croatia)) has a particular cytoprotective/adaptive cytoprotective activity.

The cytoprotective/adaptive cytoprotection researches largely neglect that stomach distension could per se jeopardize the mucosal integrity, with constantly stretched mucosa and blood vessels, and sphincters more prone for reflux induction. After absolute alcohol instillation in fully distended rat stomach, gastric, esophageal and duodenal lesions occur. Throughout next 3 min, left gastric artery blood vessels clearly disappear at the serosal site, indicative for loss of vessels both integrity and function.

Contrary, constant vessels presentation could predict the beneficial effect of applied agent. After pentadecapeptide BPC 157 instillation into the stomach the vessels presentation remains constant, and lesions of stomach, esophagus, and duodenum are inhibited. Standards (atropine, ranitidine, omeprazole) could only slightly improve the vessels presentation compared to control values, and they have only a partial effect on the lesions.

In this review we emphasize BPC 157 unusual stability, and some of its important effects: effectiveness against various lesions in gastrointestinal tract, on nitric oxide (NO)-system, and NO-agents effects, on somatosensory neurons, salivary glands function, recovery of AMP-ADP-ATP system, endothelium protection, effect on endothelin, and on angiogenesis promotion.

It also antagonizes other alcohol effects, including acute and chronic intoxication.

Given peripherally, it counteracts the consequence of central dopamine system disturbances (receptor blockade), and induces serotonin release in substantia nigra.

Therapeutic potential of BPC 157 as a cytoprotective agent is also seen in its capability to heal various wounds.

Given directly into the stomach, BPC 157 instantly recovers disturbed lower esophageal and pyloric sphincter pressure in rats after 12–20 months of untreated esophagitis.

All these could be suggestive for its role as a natural protectant in gastric juice with particular function throughout stomach distension.
Key words.
Stable Gastric Pentadecapeptide BPC 157-PL 10 PLD 116 PLD 14736 Cytoprotective agent Healing


Source for this article:


BPC 157: The Healing Miracle Molecule

What is BPC 157?

The human body has a remarkable system of self-healing and damage repair. One of the important components of this system is a protein called Body Protection Compound (BPC) 157.

BPC 157 is a peptide made up of 15 amino acids; and is produced by the body in the acidic environment of the stomach. The peptide is well-known for its ability to heal, repair and regenerate. Studies suggest that BPC 157 is useful in the treatment of ulcers in the digestive tract as well as management of inflammatory bowel disease (IBD), a group of inflammatory disorders of the digestive tract. BPC 157 also facilitates wound healing of various tissues, including skin, muscle, bone, ligament, and tendon.

BPC 157 in the Digestive Tract

Given that BPC 157 is present in the juices of the stomach, we would expect it to be involved in functioning of the digestive tract. And this is indeed the case. In fact, BPC 157 is also called “stable gastric pentadecapeptide”as it remains stable in human gastric juices for at least 24 hours.

BPC 157 has several functions in the digestive tract. It preserves the integrity of the stomach lining, improves digestion, and facilitates healing throughout the digestive tract. It is particularly helpful in [1] [2]:

  1. Inflammatory bowel disease; such as Ulcerative Colitis, Crohn’s Disease and Esophagitis
  2. Fistula and intestinal anastomosis (the latter is a process where a section of an intestine is cut and removed. The two ends are then surgically connected.)
  3. Reversing short bowel syndrome
  4. Protecting the gastro-intestinal tract from NSAID overuse

Much of the healing capacity of BPC 157 comes from its ability to:

  • Protect the endothelium – inner lining of blood vessels and the lymphatic system known as the endothelium,
  • Play an important role in the formation of new blood vessels – a process known as angiogenesis.

BPC 157 as an Anti-ulcer Agent

BPC 157 is a cytoprotective agent; meaning it can limit the damage to gastric mucosa by agents that trigger ulcer formations. Most importantly, it doesn’t prevent gastric acid secretion but strengthens the protection for gastric mucosa.

NSAID’s or non-steroidal anti-inflammatory drugs are commonly used to relieve pain and inflammation. Overuse of NSAIDs is known to cause ulcers and even bleeding in the digestive tract. BPC 157 possesses the ability to heal these ulcers and a study published in 2013 noted that BPC 157 has clear antidote activity against NSAIDS side effects; and that the “variety of the beneficial effects portrayed by BPC 157 may well be a foundation for establishing BPC 157 as a NSAIDs antidote since no other single agent has portrayed a similar array of effects.” [3]

In addition, BPC 157 can heal lesions in the liver developed due to overuse of alcohol. These lesions can lead to liver tissue damage. Thus, BPC 157 can protect the liver from further deteriorating.

BPC 157 in Inflammatory Bowel Disease

BPC 157 shows great potential in reducing the symptoms of advanced inflammatory bowel disease (IBD). The peptide combines its anti-inflammatory and healing properties to manage the following conditions:

  • Crohn’s disease: chronic inflammation affecting the digestive tract. It causes abdominal pain, diarrhea, and poor absorption of nutrients leading to fatigue and malnutrition.
  • Ulcerative colitis: formation of ulcers and open sores in the colon
  • Esophagitis: inflammation of the esophagus (food pipe) making it extremely painful and difficult swallow.

BPC 157 in Wound Healing

Wound healing is a complex process involving a sequential, cascade of events; which are critical for maintaining the integrity of the body.

BPC 157 holds tremendous potential in wound healing of many tissues such as skin, muscle, bone, ligaments, and tendons. It reduces inflammation at the wound site and allows faster healing of bone ligaments, damaged muscle, Achilles tendons and skin wounds [4] [5].

There are three major processes by which BPC 157 plays a vital role in wound healing; angiogenesis, granulation tissue formation, and production of collagen. All of these mechanisms are central to any healing process occurring within the body.

Angiogenesis is a process where new blood vessels are formed around the site of injury. It allows new blood vessels to send oxygen, nutrients, and inflammatory cells to the healing and regenerating tissues. BPC 157 increases the expression of vascular endothelial growth factor (VEGF) that promotes angiogenesis [6].

A quick primer on VEGF

VEGF is a protein that signals the growth of new blood vessels when a tissue is damaged. It is a very important process that serves to reinstate the blood supply; and with it oxygen and nutrition, to the tissues at the time of reduced blood circulation. In other words, during an injury, the growth factor triggers the sprouting of new blood vessels – an action that increases the influx of nutrients to the damaged tissue.

BPC 157 exerts a particularly effective role in tendon healing. Muscles have a remarkable process of healing; owing to a highly-evolved system of blood vessels and also stem cells. However, tendons lack this blood vessel network and as a result there is a reduced flow of oxygen and nutrients to the recuperating tendon. This leads to impaired healing.

BPC 157, by up-regulating VEGF, triggers an adequate and controlled angiogenic response that allows tendons to heal faster. Controlled angiogenesis is important, as prolonged instances interferes in healing, eventually leading to chronic tendon disease.

BPC 157 achieves effective muscle and tendon healing by regulating certain underlying complex processes, “In tendon and muscle healing its functional, biomechanical, and pathohistological beneficial effect is accompanied by angiogenic action. BPC 157 may directly protect endothelium, influence the NO-system, counteract the effect of both NOS-inhibitor and NO-precursor as well as over expression of endothelin.”

The anti-inflammatory properties of BPC 157 further contribute to its healing benefits. The peptide decreases the concentration of inflammatory mediators in the injured or damaged tissues – promoting the wound healing process and allowing the tissue to heal faster.

BPC Influences the NO system

BPC 157 interacts with, and modulates the nitric oxide (NO) system; an important property responsible for many of its wound healing and tissue repair outcomes.

NO is a gas naturally produced by the body and is implicated in many aspects of repair, healing and regeneration processes – involving angiogenesis, inflammation, cell proliferation, matrix deposition, and remodeling to name a few. Nitric oxide plays a particularly important role in mediating a number of inflammatory responses and promoting angiogenesis (growth of new blood vessels).

Furthermore, a study showed that the protein’s ability to influence the NO system may be helpful in many conditions [7]:

  1. Protects the gastric mucosa following alcoholic lesions
  2. Alcohol intoxication and withdrawal
  3. Cardiovascular problems, including chronic heart failure, irregular heart beat and elevated blood pressure in the arteries of the lungs
  4. Changes in blood potassium levels that can lead to dysfunction of the cell membranes
  5. Complications with fistula healing; both of colon and esophagus.

BPC 157 is safe with no side effects

BPC 157 is naturally produced by the body in small amounts. There are no reported side effects associated with its use. With no Lethal Dose 1 achieved for BPC 157, it enjoys quite a high safety profile. Lethal Dose 1 of any substance is the dose at which 1 % of the test population is killed.

BPC 157 Benefits in a Nutshell

Miraculous healing protein

  1. Anti-ulcer and provides protection to the gastric mucosa
  2. Provides relief in inflammatory bowel disease; including Ulcerative Colitis and Crohn’s Disease
  3. Promotes healing in intestinal surgery and fistula
  4. Promotes faster healing of damaged muscle and tendons.
  5. Improved healing of superficial cuts, skin wounds and abrasions



  1. Cesarec V, Becejac T, Misic M, Djakovic Z, Olujic D, Drmic D, Brcic L, Rokotov DS, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy. European Journal of Pharmacology. 2013
  2. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.  Current Pharmaceutical Design. 2011
  3. P Sikiric et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 2013
  4. Chang CH, Tsai WC, Hsu YH, Pang JH. BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014
  5. Krivic, A., Anic, T., Seiwerth, S., Huljev, D. and Sikiric, P. Achilles Detachment in Rat and Stable Gastric Pentadecapeptide BPC 157: Promoted Tendon-to-Bone Healing and Opposed Corticosteroid Aggravation. . J. Orthop. 2006
  6. L. Brcic et al. Modulatory Effect Of Gastric Pentadecapeptide Bpc 157 On Angiogenesis In Muscle And Tendon Healing. Journal of Physiology And Pharmacology 2009
  7. P Sikiric et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Current Pharmaceutical Design. 2014


Beneficial effect of BPC 157 on gastric lesions

This trial demonstrates the synergistic activity of BPC157 with certain neurons!

Digestive Diseases and Sciences Journal

August 1996, Volume 41, Issue 8, pp 1604-1614

Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity


Very recently, the integrity of capsaicin somato sensory neurons and their protection were suggested to be related to the activity in nociception of a newly discovered 15-amino acid peptide, BPC 157, shown to have strong beneficial effect on intestinal and liver lesions.

Therefore, from this viewpoint, we have studied the gastroprotective effect of the pentadecapeptide BPC 157, on gastric lesions produced in rats by 96% ethanol, restraint stress, and indomethacin.

The possible involvement of sensory neurons in the salutary actions of BPC 157 (10µg/kg, 10 ng/kg intraperitoneally) was studied with capsaicin, which has differential effects on sensory neurons: a high dose in adult (125 mg/kg subcutaneously, 3 months old) or administration (50 mg/kg subcutaneously) to neonatal animals (age of the 7 days) destroys sensory fibers, whereas a low dose (500µg/kg intraperitoneally) activates neurotransmitter release and protective effects on the mucosa.

In the absence of capsaicin, BPC 157 protected gastric mucosa against ethanol, restraint, and indomethacin application. In the presence of neurotoxic doses of capsaicin, the negative influence of capsaicin on restraint, ethanol, or indomethacin lesions consistently affected salutary activity of BPC 157.

However, BPC 157 protection was still evident in the capsaicin-treated rats (either treated as adults or as newborns) in all of these assays. Interestingly, after neonatal capsaicin treatment, a complete abolition of BPC gastroprotection was noted if BPC 157 was applied as a single nanogram-regimen, but the mucosal protection was fully reversed when the same dose was used daily. In line with the excitatory dose of capsaicin the beneficial effectiveness of BPC 157 appears to be increased as well.

Taken together, these data provide evidence for complex synergistic interaction between the beneficial effectiveness of BPC 157 and peptidergic sensory afferent neuron activity.


Key words
pentadecapeptide BPC 157 organoprotective peptide gastric lesions capsaicin neurotoxicity rats gastroprotection neuroprotection


Source for this article:


Useful Cited References:

  • 12. Sikiric P, Petek M, Rucman R, Rotkvic I, Seiwerth S, Grabarevic Z, Jagic V, Turkovic B, Mildner B, Duvnjak M, Cviko A, Kolega M, Dodig M, Sallmani A, Djacic S, Lucinger D, Erceg D: The significance of the gastroprotective effect of body protection compound (BPC): modulation by different procedures.In Cell Injury and Protection in the Gastrointestinal Tract: From Basic Sciences to Clinical Perspectives. Gy Mózsik, A Pár, G Csomós, M Kitajima, M Kondo, CJ Pfeiffer, KD Rainsford, P Sikiric, S Szabo (eds). Budapest, Akedémiai Kiadó, 1992, pp 89–98
  • 13. Sikiric P, Petek M, Rucman R, Seiwerth S, Grabarevic Z, Rotkvic I, Jagic V, Mildner B, Duvnjak M, Lang N: A new gastric juice peptide, BPC-an overview of stomach/stress/organoprotection hypothesis and BPC beneficial effects. J Physiol (Paris) 87:313–327, 1993
  • 14. Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Rotkvic I, Turkovic B, Jagic V, Mildner B, Duvnjak M, Danilovic Z: Hepatoprotective effect of BPC 157, a 15-aminoacid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin. Life Sci 53:PL291-PL296, 1993
  • 15. Sikiric P, Gyires K, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Rotkvic I, Turkovic B, Udovicic I, Jagic V, Mildner B, Duvnjak M, Danilovic Z: The effect of pentadecapeptide BPC 157 on inflammatory, non-inflammatory, direct and indirect pain and capsaicin neurotoxicity. Inflammopharmacology 2:121–127, 1993
  • 16. Sikiric P, Seiwerth S, Grabarevic Z, Petek M, Rucman R, Turkovic B, Rotkvic I, Jagic V, Duvnjak M, Mise S, Djacic S, Separovic J, Veljaca M, Sallmani A, Banic M, Brkic T: The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duododenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promoters and gut peptides. Life Sci 54:PL63-PL68, 1994
  • 18. Mózsik Gy, Sikiric P, Petek M: Gastric mucosal preventing body protective compound (BPC) effect on the development of ethanol and HCl-induced gastric mucosal injury. Exp Clin Gastroenterol 1:87–90, 1991
  • 19. Paré W, Klucyznski JM: The effect of new gastric juice peptide BPC on classic stress triad in stress procedure. Exp Clin Gastroenterol 2:234–236, 1992
    Veljaca M, Pllana R, Lesch CA, Sanchez B, Chan K, Guglietta A: Protective effect of BPC 157 on a rat model of colitis. Gastroenterology 106:789, 1994
  • 21. Veljaca M, Lech CA, Pllana R, Sanchez B, Chan K, Guglietta A: BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol Exp Ther 272:417–422, 1994
  • 22. Veljaca M, Lesch CA, Sanchez B, Low J, Guglietta A: Protection of BPC-15 on TNBS-induced colitis in rats: possible mechanisms of action. Gastroenterology 108:936, 1995
  • 23. Veljaca M, Chan K, Guglietta A: Digestion of h-EGF, h-TGF alpha, and BPC-15 in human gastric juice. Gastroenterology 108:761, 1995
  • 48. Kalogjera L, Ries N, Baudoin T, Ferencic Z, Seiwerth S, Sikiric P: Dose dependent protective effect of BPC 157 in capasaicin induced rhinitis in rats. European Arch Otorhynolaringol 1996 (in press)


This trial shows the effectiveness of BPC157 on damages caused by insulin over dosage, which can be very useful for diabetics who inject themselves too much insulin… extracts:



The general significance of insulin induced ulcers remains not determined. We focused on hyperinsulinemia, deliberate injection of excessive insulin, and possibility that an anti-ulcer therapy with anti-ulcer peptide may be more successful counteracting therapy.

Insulin induced ulcers were long ago described, and related to gastric acid hypersecretion (1, 2).

Thus, to provide some novel intriguing insights, we focused on insulin induced gastric ulcers (1, 2) and then on other disturbances that may be concomitantly induced by insulin application (3-5).


We focused on a peptide therapy, using a small, orally active, anti-ulcer peptide (7-11) stable gastric pentadecapeptide BPC 157 (MW 1419) with very safe profile (LD1 could be not achieved, no side effects in clinical trials (12, 13) stable in human gastric juice (14), effective in trials for inflammatory bowel disease therapy (12, 13) and wound healing (15-18) also in diabetic rats (18, 19).

Importantly, pentadecapeptide BPC 157 was more active than recombinant human platelet-derived growth factor (PDGF-BB), stimulating both expression of early growth response 1 (egr-1) gene and its repressor nerve growth factor 1- A binding protein-2 (NAB2) (18).

Thereby, it may be important for cytokine induction, growth factor generation, early extracellular matrix (collagen) formation (18), but also for gluconeogenesis regulation (20).

Finally, alloxan-gastric ulcers in rats and mice may be inhibited by stable gastric pentadecapeptide BPC 157 (21).



Thus, when given to insulin-rats, BPC 157 would be confronted with the all processes simultaneously occurring that eventually lead to stomach ulcer (1, 2), hypoglycemia and all mentioned disturbances and death in insulin over-dose-rats (3-5). However, we shown that pentadecapeptide BPC 157, as an antiulcer peptide (7-11), may besides stomach ulcer consistently counteract all insulin disturbances and fatal outcome. This may also indicate that these disturbances are also interconnected throughout BPC 157 background. Moreover, considering the used insulin (250 IU/kg i.p.) /BPC 157 (10 µg, 10 ng/kg i.p. or i.g.) ratio (7, 8), it may be reasonably to assume that these therapy effects may indicate a likely role of BPC 157 in insulin controlling and influence on one or more causative process(es).


In conclusion, these findings demonstrate that when one application of very high dose of insulin may induce together stomach ulcer, seizures, severely damaged neurons in cerebral cortex and hippocampus, hepatomegaly, fatty liver, breakdown of liver glycogen with profound hypoglycemia, along with calcium deposition, and finally fatal outcome in rats, all damages were markedly attenuated when BPC 157 was applied.

The same effectiveness when given intraperitoneally or intragastrically (i.e., stable in human gastric juice (14)) may be suggestive that BPC 157 may have also an incretin role in controlling insulin effects (7, 8, 11).

Intriguingly, further studies may show whether standard anti-ulcer agents that prevent insulin-stomach ulcer (1, 2) may also have a broader beneficial effect on other disturbances presented in insulin-rats.

Previously, BPC 157 was shown to counteract toxic effects of other insulin preparations (43).


Source for this article:


Useful References:

  • 7. Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol (Paris) 1993; 87: 313-327.
  • 8. Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology 2006; 14: 214-221.
  • 9. Sikiric P, Siwerth S, Grabarevic Z, et al. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesion induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promoters and gut peptides. Life Sci 1994; 54: 63-68.
  • 10. Sikiric P, Seiwerth, S, Grabarevic Z, et al. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol 1997; 332: 23-33.
  • 11. Sikiric P, Seiwerth S, Grabarevic Z, et al. Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats. Dig Dis Sci 1996; 41: 1518-1526.
  • 12. Veljaca M, Pavic-Sladoljev D, Mildner B, et al. Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers. Gut 2003; 51: A309.
  • 13. Ruenzi M, Stolte M, Veljaca M, Oreskovic K, Peterson J. A multicenter, randomized, double blind, placebo-controlled phase II study of PL 14736 enema in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology 2005; 128: A584.
  • 14. Veljaca M, Chan K, Guglietta A. Digestion of h-EGF, h-TGF alpha and BPC 157 in human gastric juice. Gastroenterology 1995; 108: 761.
  • 15. Sikiric P, Seiwerth S, Mise S, et al. Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice. Burns 2003; 29: 323-334.
  • 16. Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today 2008; 38: 716-725.
  • 17. Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: gastric pentadecapeptide BPC 157. J Orthop Res 2006; 24: 1109-1117.
  • 18. Tkalcevic VI, Cuzic S, Brajsa K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol 2007; 570(1-3): 212-221.
  • 20. Berasi SP, Huard C, Li D, et al. Inhibition of gluconeogenesis through transcriptional activation of EGR1 and DUSP4 by AMP-activated kinase. J Biol Chem 2006; 281: 27167-27177.
  • 21. Petek M, Sikiric P, Anic T, et al. Pentadecapeptide BPC 157 attenuates gatric lesions induced by alloxan in rats and mice. J Physiol (Paris) 1999; 93: 501-504.
  • 43. Ilic S, Mester M, Filipovic M, et al. Stable gastric pentadecapeptide BPC 157 and insulin induced gastric lesions in rats. J Physiol Pharmacol 2009; 60(Suppl 2): 40.

Effect of BPC 157 on direct and indirect pain and capsaicin neurotoxicity

This trial indicates the strong potential of BPC157 against abdominal pain.

Inflammo Pharmacology Journal
June 1993, Volume 2, Issue 2, pp 121-127

The effect of pentadecapeptide BPC 157 on inflammatory, non-inflammatory, direct and indirect pain and capsaicin neurotoxicity


The anti-nociceptive effects of a newly synthesized pentadecapeptide coded BPC 157 (an essential fragment of new organoprotective gastric juice peptide BPC) was evaluated in comparison with aspirin and morphine reference standards, in various experimental models of indirect/direct nociception and neurotoxicity: writhing (acetic acid/magnesium sulphate), tail pinching, hot-plate, and capsaicin application.

BPC 157 administered either in the ng or μg per kg range, intraperitoneally, significantly reduced the reactions in the writhing (inflammatory and non-inflammatory, prostaglandin-dependent and independent) and tail pinching tests.

In the hot-plate test, unlike morphine, BPC 157 had no effect on normal animals. However, when given to capsaicin treated rats, BPC 157 strongly reduced capsaicin-allodynia, either given as pretreatment or once daily for 14 days after the capsaicin injection.

This reduction in capsaicin’s effect could not be obtained when BPC 157 was applied in the presence of established capsaicin-somatosensory neuron degeneration (application only on the 14th day after capsaicin), so it is possible that the effects of BPC 157 could be related specifically to the integrity of capsaicin-sensitive somatosensory neurons and their protection (e.g. primary afferent neurons having small-diameter somata and unmyelinated (C-) or thinly myelinated (A6-) fibres).


pentadecapeptide BPC 157 essential fragment of organoprotective gastric juice peptide BPC writhing (acetic acid/magnesium sulphate) tail pinching test hot-plate test inflammatory/non-inflammatory, indirect/direct nociception capsaicin allodynia capsaicin-sensitive somatosensory neurons integrity/protection

Source for this article:


Useful Cited References:

  • 2. Sikirić P, Petek M, Rotkvic I et al. Antiulcerogenic and antiinflammatory effect of a new gastric juice peptide – body protection compound. Exp Clin Gastroenterol. 1991;l:17–20.
  • 3. Sikirif P, Sciwerth S, Grabarevif Z et al. The significance of the gastroprotective effect of body protection compound (BPC): modulation by different procedures. Acta Physiol Hung. 1992;80:89–98.
  • 4. Sikirif P, Petek M, Rucman R et al. A new gastric juice peptide, BPC – an overview of stomach/stress/organoprotection hypothesis and BPC beneficial effects. J Physiol (Paris). 1993;87 [in press].
  • 5. Mppozsik G, Sikirif P, Petek M. Gastric mucosal preventing body protective compound (BPC) on the development of ethanol and HCl-induced gastric mucosal injury. Exp Clin Gastroenterol. 1991;l:87–90.